Tirzepatide® providers &
prescriptions in Greensboro, NC
Verified Tirzepatide providers in Greensboro, NC. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]
Find a Tirzepatide provider in North Carolina.
Every entry is checked against the NPI registry and the North Carolina medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.
How to get Tirzepatide in Greensboro.
32 GLP-1 prescribers and 7 local resource types are on record for Greensboro, plus 3 nearby towns in the directory.
Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm North Carolina’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.
The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.
Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]
In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]
Community health · CDC
Weight & metabolic health in North Carolina
Diagnosed diabetes reaches 11% of adults in North Carolina.
- of North Carolina adults have obesity
- 34.5%
- diagnosed diabetes
- 11%
Age-adjusted estimates for North Carolina, community figures, not individual risk. CDC BRFSS 2024.
The prescription is one part. Here is the rest, in Greensboro.
Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Greensboro, NC, ordered as the registry lists them, never by who pays us.
Nutritionists
A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.
5100 Mackay Rd
1100 E Wendover Ave
Gyms near you
A gym gives you the regular movement that keeps muscle while the weight comes off.
What the trials actually showed.
We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.
Most side effects are gastrointestinal and resolve within weeks.
The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]
Most directories hide the price. We don't.
Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.
Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.
NPI-verified Tirzepatide (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.
Find NPI-verified Tirzepatide (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.
The questions people ask before they book.
Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.
Yes. Tirzepatide is the active molecule in both Eli Lilly products. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They are the same drug with different approved indications, and insurers treat them as separate products.[1]